Literature DB >> 2149949

Immunology of Down syndrome: a review.

A G Ugazio1, R Maccario, L D Notarangelo, G R Burgio.   

Abstract

Subjects with Down syndrome (DS) have a high mortality due to infections and a high risk of developing malignancies. These observations, together with the demonstration of a frequent occurrence of HBsAg carrier state and of autoantibodies, have prompted investigations of the immune function in DS. Thymic morphological and functional abnormalities have been demonstrated. Peripheral blood mononuclear cells of DS subjects have been shown to include a high number of T lymphocytes with low avidity for sheep erythrocytes and a very high percentage of cells with an NK phenotype. However, NK activity is low in DS. Production of some important cytokines, such as IL-2, is depressed, thus contributing to T-cell derangement. Abnormalities of the B-cell compartment were also demonstrated, with a tendency towards high IgG and low IgM serum levels. Controversial results have been obtained with regard to antigen-specific antibody response. Also phagocytes of DS subjects display some characteristic functional impairments, with low chemotactic ability and reduced production of oxygen radicals. Despite the clearly established and rather detailed evidence of immune derangements, therapeutic trials have been anecdotal and resulted in marginal effects. HBV vaccination is highly advisable in DS because of the high risk of becoming chronic HBV carriers once infected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149949     DOI: 10.1002/ajmg.1320370742

Source DB:  PubMed          Journal:  Am J Med Genet Suppl        ISSN: 1040-3787


  27 in total

1.  Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down's syndrome?

Authors:  J P Shield; E J Wadsworth; T J Hassold; L A Judis; P A Jacobs
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

2.  Primary sclerosing cholangitis preceding Crohn's disease in a child with Down's syndrome.

Authors:  P Vajro; S Cucchiara; A Vegnente; R Iorio; C de Silva; L Cipolletta; M A Bianco
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

3.  High positivity of anti-CCP antibodies in patients with Down syndrome.

Authors:  Renato M Nisihara; Thelma L Skare; Marília B G Silva; Iara T Messias-Reason; Nanci P Oliveira; Patricia T Fiedler; Shirley R R Utiyama
Journal:  Clin Rheumatol       Date:  2007-03-27       Impact factor: 2.980

Review 4.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

5.  Low bone turnover and low bone density in a cohort of adults with Down syndrome.

Authors:  K D McKelvey; T W Fowler; N S Akel; J A Kelsay; D Gaddy; G R Wenger; L J Suva
Journal:  Osteoporos Int       Date:  2012-08-18       Impact factor: 4.507

6.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

7.  Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field.

Authors:  M E Coussons-Read; L S Crnic
Journal:  Behav Genet       Date:  1996-01       Impact factor: 2.805

8.  Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes.

Authors:  H Vaziri; F Schächter; I Uchida; L Wei; X Zhu; R Effros; D Cohen; C B Harley
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

Review 9.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

10.  Thyroid function and plasma immunoglobulins in subjects with Down's syndrome (DS) during ontogenesis and zinc therapy.

Authors:  M Sustrová; V Strbák
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.